
---
title: '甘李药业：GZR101中国Ⅰ期临床试验完成首例受试者给药'
categories: 
 - 金融
 - 证券时报网
 - 快讯
headimg: 'https://picsum.photos/400/300?random=2737'
author: 证券时报网
comments: false
date: Wed, 06 Jul 2022 16:34:00 GMT
thumbnail: 'https://picsum.photos/400/300?random=2737'
---

<div>   
<p>证券时报e公司讯，<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603087" style="color: #2f67d1;text-decoration: none;" code="603087" target="_blank">甘李药业</a>(603087)7月6日晚间公告，公司自主研发的GZR101已经启动中国Ⅰ期临床试验，近日成功完成首例受试者给药。GZR101是<a class="trsHotWords" href="https://info.stcn.com/dc/stock/?stockcode=SS603087" style="color: #2f67d1;text-decoration: none;" code="603087" target="_blank">甘李药业</a>在研的长效基础胰岛素GZR33与速效门冬胰岛素混合制成的双胰岛素复方制剂，拟用于治疗糖尿病。</p>

                  
</div>
            